中国は,初期段階の結腸がんに対する第一回の二項免疫療法を承認し,治療率を上げ,化学療法の必要を軽減する. China approves first dual immunotherapy for early-stage colon cancer, boosting cure rates and reducing need for chemo.

中国の国家医薬品局は,切除可能なIIB-III段階のMSI-H/dMMR大腸がんのネオアジュバン治療のために,Inovent BiologicsのTABOSUN® (ipilimumab N01注射) とTYVYT® (sintilimab) を併用することを承認した. China's National Medical Products Administration has approved Innovent Biologics' TABOSUN® (ipilimumab N01 injection) combined with TYVYT® (sintilimab) for neoadjuvant treatment of resectable stage IIB-III MSI-H/dMMR colon cancer. この二重免疫腫瘍療法が この用途で承認された 世界初の治療法であり, 病理的な完全応答率を大幅に改善しています This dual immune-oncology regimen is the first and only such therapy globally approved for this use, significantly improving pathological complete response rates. この承認は,化学療法後の化学療法の必要性をなくし,再発のリスクを軽減する可能性がある. The approval offers a new option for a colon cancer subset with limited chemotherapy response, potentially eliminating the need for post-surgery chemotherapy and reducing recurrence risk.